正在加载公司
Just reported
Q3 2026 results
From Editas Medicine's results release of 2026年11月9日; its quarterly report has since been filed.
Revenue
Actual
US$10.4M
+37% y/y
-13% q/qGuided
—
No guide given
EPS, GAAP
Actual
-US$0.15
Guided
—
No guide given
Operating income, GAAP
Actual
-US$24.3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Editas Medicine is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.US$47.5BA+
EXELExelixis, Inc.US$17BA+
JAZZJazz Pharmaceuticals plcUS$15.4BA
HALOHalozyme Therapeutics, Inc.US$11.5BA+
TECHBIO-Techne CorpUS$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
怎么赚钱
- Licensing and research collaborations100%
各项收入占比是对FY2025的估算，并非来自已提交报告的数字。
竞争对手
卖什么3
EDIT-401
An experimental one-time treatment designed to edit liver cells so they produce more of a protein that removes LDL cholesterol from the blood. It was being prepared for a Phase 1/2 human trial in people with inherited high cholesterol.
In-vivo blood stem-cell editing program
A research program intended to edit blood-forming stem cells inside the body to raise fetal hemoglobin, with the aim of treating sickle cell disease and transfusion-dependent beta thalassemia.
Cas9 and Cas12a gene-editing technology
Gene-editing tools that Editas licenses to partners for research and development of medicines, including treatments that modify immune cells.
谁在买3
- Bristol Myers Squibb: collaborates on research into gene-edited immune-cell treatments and may make milestone and royalty payments.
- Vertex Pharmaceuticals: licenses Editas gene-editing technology for medicines targeting inherited blood disorders and pays annual license fees.
- Immatics: collaborates with Editas on gene-edited immune-cell treatments for cancer.
靠什么支撑，什么会击垮它
业务依赖什么
- 1The business depends heavily on EDIT-401, its lead medicine, and on advancing it from preclinical research into human trials.
- 2Editas licenses important gene-editing patents from universities and research institutions; those agreements require payments and compliance with their terms.
- 3It relies on outside manufacturers and service providers for research materials and planned clinical trials, and on partners and investors for funding.
可能出什么问题
- 1EDIT-401 has not yet established safety or effectiveness in people; failure or delay in its development could significantly affect the business.
- 2Gene-editing patents and licenses are subject to disputes and challenges, which could limit Editas's rights to use or license important technology.
- 3Editas has no medicine-sale revenue and needs substantial funding; if it cannot raise money or receive partner payments, it may have to cut or delay research and development.
关于Editas Medicine, Inc.
Editas develops medicines that change deoxyribonucleic acid (DNA) to treat disease. Its CRISPR (clustered regularly interspaced short palindromic repeats) technology uses a guide molecule to direct an enzyme to a chosen DNA location. Its lead medicine, EDIT-401, is being prepared for early human testing to lower low-density lipoprotein (LDL) cholesterol; the company also licenses its technology and works with drug companies on research programs.
- 总部
- Cambridge, Massachusetts
- 成立于
- 2013
- 上市于
- Nasdaq
- 财年结束
- December 31
基于 Editas Medicine, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
